Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

bemcentinib (BGB324)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BerGenBio, Rigel

Drug class:

AXL inhibitor

Related drugs:

AXL positive	Non Small Cell Lung Cancer	AXL positive	Non Small Cell Lung Cancer	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + BGB324 Sensitive: B - Late Trials pembrolizumab + BGB324 Sensitive : B	pembrolizumab + BGB324 Sensitive: B - Late Trials pembrolizumab + BGB324 Sensitive : B
AXL expression	Non Small Cell Lung Cancer	AXL expression	Non Small Cell Lung Cancer	pembrolizumab + BGB324 Sensitive: C2 – Inclusion Criteria pembrolizumab + BGB324 Sensitive : C2	pembrolizumab + BGB324 Sensitive: C2 – Inclusion Criteria pembrolizumab + BGB324 Sensitive : C2
SLFN11 expression	Myelodysplastic Syndrome	SLFN11 expression	Myelodysplastic Syndrome	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
ANG elevation	Myelodysplastic Syndrome	ANG elevation	Myelodysplastic Syndrome	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
AXL elevation	Myelodysplastic Syndrome	AXL elevation	Myelodysplastic Syndrome	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
SLFN11 expression	Acute Myelogenous Leukemia	SLFN11 expression	Acute Myelogenous Leukemia	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
ANG elevation	Acute Myelogenous Leukemia	ANG elevation	Acute Myelogenous Leukemia	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
AXL elevation	Acute Myelogenous Leukemia	AXL elevation	Acute Myelogenous Leukemia	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab + BGB324 Sensitive: C3 – Early Trials pembrolizumab + BGB324 Sensitive : C3	pembrolizumab + BGB324 Sensitive: C3 – Early Trials pembrolizumab + BGB324 Sensitive : C3
KRAS mutation + PD-L1 negative	Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation + PD-L1 negative	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab + BGB324 Sensitive: C3 – Early Trials pembrolizumab + BGB324 Sensitive : C3	pembrolizumab + BGB324 Sensitive: C3 – Early Trials pembrolizumab + BGB324 Sensitive : C3